Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Primo N Lara

Showing results (111-120 of 274) with videos related to

Pageof 28
Sort By:
Seminars in Oncology|March 15, 2002
Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxiaDavid R Gandara, Primo N Lara, Zelanna Goldberg, et al.
Investigational New Drugs|April 19, 2007
Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I studyAngela M Davies, Cheryl Ho, Paul J Hesketh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancerDavid Gandara, Samir Narayan, Primo N Lara, et al.
Cancer Chemotherapy and Pharmacology|June 7, 2011
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapyWilliam S Holland, Clifford G Tepper, Jose E Pietri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancerGigi Chen, Minh Huynh, Lou Fehrenbacher, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)Angela M Davies, Kari Chansky, Primo N Lara, et al.
Acta Pharmaceutica Sinica. B|October 6, 2023
Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancerYixin Chen, Mei-Juan Tu, Fangwei Han, et al.
Anti-Cancer Drugs|April 28, 2009
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium studyPrimo N Lara, Jeff Longmate, Christopher P Evans, et al.
Urology|July 22, 2010
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium TrialPrzemyslaw Twardowski, Walter M Stadler, Paul Frankel, et al.
Clinical Lung Cancer|June 9, 2012
Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneityDavid R Gandara, Tianhong Li, Primo N Lara, et al.
Pageof 28

Showing results (111-120 of 274) with videos related to

Sort By:
Pageof 28
Seminars in Oncology|March 15, 2002
Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxiaDavid R Gandara, Primo N Lara, Zelanna Goldberg, et al.
Investigational New Drugs|April 19, 2007
Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I studyAngela M Davies, Cheryl Ho, Paul J Hesketh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancerDavid Gandara, Samir Narayan, Primo N Lara, et al.
Cancer Chemotherapy and Pharmacology|June 7, 2011
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapyWilliam S Holland, Clifford G Tepper, Jose E Pietri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancerGigi Chen, Minh Huynh, Lou Fehrenbacher, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)Angela M Davies, Kari Chansky, Primo N Lara, et al.
Acta Pharmaceutica Sinica. B|October 6, 2023
Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancerYixin Chen, Mei-Juan Tu, Fangwei Han, et al.
Anti-Cancer Drugs|April 28, 2009
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium studyPrimo N Lara, Jeff Longmate, Christopher P Evans, et al.
Urology|July 22, 2010
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium TrialPrzemyslaw Twardowski, Walter M Stadler, Paul Frankel, et al.
Clinical Lung Cancer|June 9, 2012
Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneityDavid R Gandara, Tianhong Li, Primo N Lara, et al.
Pageof 28